目的 研究Pax-2在各类型肾细胞癌中的表达的差异,探讨它与肾细胞癌的临床诊断及预后的意义.方法 运用免疫组织化学SP法检测Pax-2在73例肾细胞癌和19例癌旁正常肾组织中的表达,结合实验数据及相关研究资料,分析其与肾细胞癌病理特征关系.结果 Pax-2在肾细胞癌中总的阳性表达率为73.97% (54/73),透明细胞癌中的阳性表达率为84.85%(28/33),在乳头状细胞癌中的阳性表达率为70.00%(14/20),在嫌色细胞癌中的阳性表达率为60.00%(12/20),正常肾组织中阳性表达率为10.53%(2/19).肾细胞癌的总阳性表达率明显高于正常肾脏组织,两者差异具有统计学意义(χ2=25.479,P=0.000).Pax-2在肾细胞癌中的表达与临床分期(χ2=4.852,P=0.026)、病理分级(χ2=5.532,P=0.019)、淋巴结转移(χ2=3.886,P=0.049)有关;而与患者性别(χ2=1.301,P=0.254)、年龄(χ2=0.723,P=0.394)及病理类型(χ2=4.219,P=0.121)无关.结论 pax-2可能为肾细胞癌的诊疗及预后的评估提供了分子水平方面的参考新指标.%Objective To research Pax-2 expression in various types of renal cell carcinoma, and to discuss the significance ot clinical diagnose and prognosis with RCC. Methods The method of immunohistochemistry SP was used to detect the expression of Pax-2 in 73 cases of renal cell carcinoma and 19 patients with normal renal tissue. The experiment analyzed the relationship between Pax-2 and pathological features of the renal cell carcinoma using immunohistochemistry SP combined with experimental data and clinical information. Results The overall positive rate of Pax-2 expression in renal cell carcinoma was 73. 97% ( 54/73) . In clear cell carcinoma, the positive expression rate was 84. 85%(28/33) . The positive expression in the papillary cell carcinoma was 70. 00% (14/20) and 60. 00% (12/20) in chromophobe renal cell carcinoma. The positive expression rate was 10. 53% (2/19) in normal renal tissue. The total positive rate of renal cell carcinoma was significantly higher than that of normal renal tissue. The difference was statistically significant (x2 =25.479, P = 0. 000 <0. 05) . Pax-2 expression in renal cell carcinoma related with clinical stage (x2 =4. 852, P = 0. 026) , pathological grade (x2 =5. 532, P =0. 019) and lymph node metastasisrn( x2 =3. 886. P =0.049) . but it unrelated with gender (x2 =1.301. P= 0.254) . age (x2 =0. 723. P =0. 394) and pathological type ( x2 =4.219. P =0. 121) . Conclusion Pax-2 could offer a molecular index for the assessment of diagnosis and prognosis in renal cell carcinoma.
展开▼
